Enliven Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ELVN Nasdaq 2836 www.enliventherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enliven Therapeutics, Inc.

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - Aug 5th, 2026 2:05 pm
Profitable Biotechs Strut Their Stuff As Stock Market Stumbles - Jul 17th, 2026 11:38 am
HMI Capital Pares Its Stake in AI Company nCino - Jul 10th, 2026 5:26 pm
Stocks To Watch: 14 Names Test And Tease New Buy Zones - Jul 8th, 2026 2:10 pm
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags - Jul 4th, 2026 12:10 am
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% - Jun 27th, 2026 1:56 pm
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally - Jun 27th, 2026 10:23 am
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN? - Jun 24th, 2026 1:32 pm
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Jun 15th, 2026 2:40 pm
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial - Jun 13th, 2026 1:02 am
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Jun 12th, 2026 12:22 pm
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of SpaceX Debut - Jun 12th, 2026 7:15 am
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - Jun 11th, 2026 8:37 pm
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Jun 11th, 2026 2:05 pm
Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN) - Jun 11th, 2026 8:36 am
Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial - Jun 11th, 2026 7:11 am
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components - Jun 11th, 2026 6:00 am